23 May 2013
Keywords: imclone, mystry, bidder, eli, lilly, biotechnology, firm
Article | 06 October 2008
US biotechnology firm ImClone, now the subject of a hostile $62 a share bid from Bristol-Myers Squibb (Marketletters passim), has revealed
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 October 2008
© 2013 thepharmaletter.com